WO2004093821A3 - Treatment of anthrax infection using inhibitors of lethal factor protease activity - Google Patents

Treatment of anthrax infection using inhibitors of lethal factor protease activity Download PDF

Info

Publication number
WO2004093821A3
WO2004093821A3 PCT/US2004/013737 US2004013737W WO2004093821A3 WO 2004093821 A3 WO2004093821 A3 WO 2004093821A3 US 2004013737 W US2004013737 W US 2004013737W WO 2004093821 A3 WO2004093821 A3 WO 2004093821A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
treatment
protease activity
lethal factor
anthrax infection
Prior art date
Application number
PCT/US2004/013737
Other languages
French (fr)
Other versions
WO2004093821A2 (en
Inventor
Mark Evan Goldman
Sean O'malley
Ondrej Simo
Melissa Nagata
Guan-Sheng Jiao
Klaus Thomas Hemscheidt
Peng Cho Tang
Lynne Cregar
Original Assignee
Hawaii Biotech Inc
Mark Evan Goldman
Sean O'malley
Ondrej Simo
Melissa Nagata
Guan-Sheng Jiao
Klaus Thomas Hemscheidt
Peng Cho Tang
Lynne Cregar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hawaii Biotech Inc, Mark Evan Goldman, Sean O'malley, Ondrej Simo, Melissa Nagata, Guan-Sheng Jiao, Klaus Thomas Hemscheidt, Peng Cho Tang, Lynne Cregar filed Critical Hawaii Biotech Inc
Publication of WO2004093821A2 publication Critical patent/WO2004093821A2/en
Publication of WO2004093821A3 publication Critical patent/WO2004093821A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds containing spaced N and/or O, by virtue of their ability to inhibit the protease activity of lethal factor from B. anthracis, are useful in the prevention and treatment of anthrax toxicity. Libraries of these compounds are also useful as substrates for screening methods to identify LF inhibitors.
PCT/US2004/013737 2003-04-22 2004-04-22 Treatment of anthrax infection using inhibitors of lethal factor protease activity WO2004093821A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46492303P 2003-04-22 2003-04-22
US60/464,923 2003-04-22

Publications (2)

Publication Number Publication Date
WO2004093821A2 WO2004093821A2 (en) 2004-11-04
WO2004093821A3 true WO2004093821A3 (en) 2005-10-27

Family

ID=33310979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/013737 WO2004093821A2 (en) 2003-04-22 2004-04-22 Treatment of anthrax infection using inhibitors of lethal factor protease activity

Country Status (1)

Country Link
WO (1) WO2004093821A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067199A2 (en) * 2006-11-16 2008-06-05 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
PT2717896T (en) 2011-06-08 2016-12-23 Kai Pharmaceuticals Inc Therapeutic agents for regulating serum phosphorus
WO2015164289A1 (en) * 2014-04-21 2015-10-29 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
EP3350194A4 (en) 2015-09-02 2019-04-24 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
US10899785B2 (en) 2015-09-02 2021-01-26 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
WO2017037717A1 (en) 2015-09-02 2017-03-09 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
WO2017118967A1 (en) * 2016-01-05 2017-07-13 Technion Research & Development Foundation Limited Aminoglycoside derivatives and uses thereof in treating microbial infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436933B1 (en) * 2001-03-26 2002-08-20 Structural Bioinformatics Inc. Inhibitors of anthrax lethal factor activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436933B1 (en) * 2001-03-26 2002-08-20 Structural Bioinformatics Inc. Inhibitors of anthrax lethal factor activity

Also Published As

Publication number Publication date
WO2004093821A2 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
WO2007014372A3 (en) Compositions and methods for treating bacteria
MXPA06011046A (en) Certain triazole-based compounds, compositions, and uses thereof.
WO2004074244A3 (en) Pyrimidine compounds
WO2004089947A3 (en) Novel compounds having an antibacterial activity
EP2194043A3 (en) Processes and intermediates
WO2008127275A3 (en) Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
EA200800357A1 (en) NEW PHARMACEUTICAL COMPOUNDS
TW200621253A (en) 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2007072153A8 (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2006091395A3 (en) Inhibitors of akt activity
WO2007079164A3 (en) Protein kinase inhibitors
WO2004103960A3 (en) Compounds and uses thereof
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
WO2006076009A3 (en) Transcription factor modulating compounds and methods of use thereof
WO2006071762A3 (en) Pyrimidine-based inhibitors of dipeptidyl peptidase iv and methods
WO2004094386A8 (en) Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b)
WO2007103370A3 (en) Quinazoline derivatives as phosphodiesterase 10 inhibitors
WO2006110638A3 (en) Inhibitors of akt activity
EP2702988A3 (en) Novel compositions and methods for treating hyperproliferative diseases
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
WO2007120333A3 (en) Tetracyclic kinase inhibitors
WO2008036379A3 (en) Serine hydrolase inhibitors
WO2008048121A3 (en) Macrocyclic cysteine protease inhibitors and compositions thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase